Celcuity’s Strategic Advances and Clinical Trial Progress Bolster Buy Rating

Andrew Berens, an analyst from Leerink Partners, maintained the Buy rating on Celcuity (CELC – Research Report). The associated price target is $28.00.

Andrew Berens has given his Buy rating due to a combination of factors related to Celcuity’s ongoing clinical trials and strategic plans. The company has recently reported its fourth-quarter results and provided updates on its VIKTORIA-1 trial, which is evaluating the effectiveness of gedatolisib in combination with other drugs for advanced breast cancer patients. The trial’s results, particularly the progression-free survival (PFS) metrics, are anticipated to be significant in determining the drug’s clinical value.
Management’s expectation that a three-month improvement in median PFS would be considered meaningful by experts and regulators adds to the optimism. Furthermore, the potential for a favorable hazard ratio (HR) compared to existing therapies could enhance the drug’s competitive positioning. The company’s strategic moves, including the possibility of seeking real-time oncology review or priority review from the FDA, indicate a proactive approach to regulatory approval. These factors collectively support Berens’s positive outlook on Celcuity’s stock.

In another report released yesterday, Craig-Hallum also reiterated a Buy rating on the stock with a $27.00 price target.